Detalles de la búsqueda
1.
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
Future Oncol
; 20(6): 317-328, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38050764
2.
Treatment patterns and clinical outcomes among patients with relapsed/refractory classical Hodgkin's lymphoma.
Future Oncol
; 18(32): 3623-3636, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36200907
3.
Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Oncologist
; 26(5): e817-e826, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33616256
4.
Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.
Thromb J
; 12: 14, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25024644
5.
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
Clin Lymphoma Myeloma Leuk
; 24(5): e181-e190, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38433043
6.
Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs.
Leuk Lymphoma
; 64(11): 1752-1770, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37497877
7.
Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients.
J Clin Microbiol
; 50(2): 238-45, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22116149
8.
A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma.
Expert Rev Hematol
; 15(7): 607-617, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35794714
9.
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.
Leukemia
; 36(3): 772-780, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34628472
10.
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Blood Adv
; 6(2): 590-599, 2022 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34644372
11.
A clinical pathway for community-acquired pneumonia: an observational cohort study.
BMC Infect Dis
; 11: 188, 2011 Jul 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-21733161
12.
Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States.
J Med Econ
; 24(1): 469-478, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33784916
13.
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA.
Target Oncol
; 16(1): 85-94, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33284424
14.
Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices.
Expert Rev Hematol
; 13(3): 275-287, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31951774
15.
Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.
Leuk Lymphoma
; 60(4): 947-954, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30234407
16.
Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.
Leuk Lymphoma
; 60(11): 2705-2711, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31012356
17.
Current management of anemia in critically ill patients: analysis of a database of 139 hospitals.
Am J Ther
; 15(5): 423-30, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18806517
18.
Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.
Crit Care
; 11(3): R63, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17553147
19.
The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis.
J Dermatolog Treat
; 18(1): 46-52, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17373090
20.
Economic burden of atopic manifestations in patients with atopic dermatitis--analysis of administrative claims.
J Manag Care Pharm
; 13(9): 778-89, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-18062729